A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs

Author(s):
Bagot, M.; Hasan, B.; Whittaker, S.; Beylot-Barry, M.; Knobler, R.; Shah, E.; Marreaud, S.; Morris, S.; Dalle, S.; Servitje, O.; Cowan, R.; Vakeva, L.; Chaby, G.; Jonak, C.; Fox, C.P.; Ritchie, D.; Vermeer, M.H. (0000-0002-5872-4613); Stadler, R.; Romero, P.L.O.; Scarisbrick, J.; Quaglino, P.; EORTC Cutaneous T- Cell Lymp
Published
2017
Publication type
Article / Letter to editor
cutaneous T-cell lymphomamaintenance treatmentrandomized triallenalinomideanti-angiogenic
Date issued
2017-05-31
Language
English
Is part of
European Journal of Dermatology (2017), Vol. 27, no. 3, p. 286-294
hdl
1887/115790
doi
10.1684/ejd.2017.3008